Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Lilly reports long-acting, soluble insulin analogues

Nov. 1, 1996

Hypoglycemic agents disclosed by Yamanouchi

Nov. 1, 1996

Sheffield Medical Technologies and Alpha Therapeutic enter into option agreement

Nov. 1, 1996

Oncogene awarded drug discovery grant

Nov. 1, 1996

Lilly and Neurocrine collaborate in the areas of obesity and Alzheimer's disease

Nov. 1, 1996

Antiobesity proteins described by Lilly

Nov. 1, 1996

CRADA opportunity for the treatment of atherosclerosis and LCAT deficiency

Nov. 1, 1996

Mitsubishi to copromote OrthoLogic 1000 in Japan

Nov. 1, 1996

FCP-3P1 in Canadian clinical trials

Nov. 1, 1996

Canadian researchers claim hPTH analogues for osteoporosis

Nov. 1, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.